A high-density lipoprotein-mediated drug delivery system

Advanced Drug Delivery Reviews

Volumn 106, Issue , 2016, Pages 132-147

  Mo, Zhong Cheng ^a   Ren, Kun ^a   Liu, Xing ^b   Tang, Zhen Li ^a   Yi, Guang Hui ^a  

^a UNIVERSITY OF SOUTH CHINA   (China)

^b INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

Author keywords

Drug delivery; HDL; Nanoparticles; Reconstitution

Indexed keywords

BIOSYNTHESIS; DRUG DELIVERY; LIPIDS; NANOPARTICLES; PROTEINS; SYNTHESIS (CHEMICAL);

CLINICAL APPLICATION; DRUG DELIVERY VEHICLES; HIGH DENSITY LIPOPROTEIN; HIGH-DENSITY LIPOPROTEINS; MULTIFUNCTIONAL AGGREGATES; PHYSICOCHEMICAL PROPERTY; PROTEIN-PROTEIN INTERACTIONS; RECONSTITUTION;

LIPOPROTEINS;

ABC TRANSPORTER A1; AMPHOTERICIN B; APOLIPOPROTEIN M; CAVEOLIN; HIGH DENSITY LIPOPROTEIN; NANOPARTICLE; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE 1 PHOSPHATE RECEPTOR; DRUG CARRIER;

BIOGENESIS; CAVEOLA; DRUG DELIVERY SYSTEM; DRUG TARGETING; ENDOCYTOSIS; HUMAN; HYDROPHILICITY; HYDROPHOBICITY; LIPID BILAYER; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVIEW; STRUCTURE ANALYSIS; ANIMAL; BIOSYNTHESIS; CHEMICAL PHENOMENA; CHEMISTRY; METABOLISM; PROCEDURES;

ANIMALS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; LIPOPROTEINS, HDL; NANOPARTICLES;

EID: 84970002272     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2016.04.030     Document Type: Review

References (200)

1. [1] Sviridov, D., Remaley, A.T., High-density lipoprotein mimetics: promises and challenges. Biochem. J. 472 (2015), 249–259.
2. [2] Tabet, F., Lambert, G., Cuesta Torres, L.F., Hou, L., Sotirchos, I., Touyz, R.M., Jenkins, A.J., Barter, P.J., Rye, K.A., Lipid-free apolipoprotein A-I and discoidal reconstituted high-density lipoproteins differentially inhibit glucose-induced oxidative stress in human macrophages. Arterioscler. Thromb. Vasc. Biol. 31 (2011), 1192–1200.
3. [3] Yvan-Charvet, L., Pagler, T.A., Seimon, T.A., Thorp, E., Welch, C.L., Witztum, J.L., Tabas, I., Tall, A.R., ABCA1 and ABCG1 protect against oxidative stress-induced macrophage apoptosis during efferocytosis. Circ. Res. 106 (2010), 1861–1869.
4. [4] Toth, P.P., Barter, P.J., Rosenson, R.S., Boden, W.E., Chapman, M.J., Cuchel, M., D'Agostino, R.B. Sr., Davidson, M.H., Davidson, W.S., Heinecke, J.W., Karas, R.H., Kontush, A., Krauss, R.M., Miller, M., Rader, D.J., High-density lipoproteins: a consensus statement from the National Lipid Association. J. Clin. Lipidol. 7 (2013), 484–525.
5. [5] Boekholdt, S.M., Arsenault, B.J., Hovingh, G.K., Mora, S., Pedersen, T.R., Larosa, J.C., Welch, K.M., Amarenco, P., Demicco, D.A., Tonkin, A.M., Sullivan, D.R., Kirby, A., Colhoun, H.M., Hitman, G.A., Betteridge, D.J., Durrington, P.N., Clearfield, M.B., Downs, J.R., Gotto, A.M. Jr., Ridker, P.M., Kastelein, J.J., Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: a meta-analysis. Circulation 128 (2013), 1504–1512.
6. [6] Touboul, P.J., Labreuche, J., Bruckert, E., Schargrodsky, H., Prati, P., Tosetto, A., Hernandez-Hernandez, R., Woo, K.S., Silva, H., Vicaut, E., Amarenco, P., HDL-C, triglycerides and carotid IMT: a meta-analysis of 21,000 patients with automated edge detection IMT measurement. Atherosclerosis 232 (2014), 65–71.
7. [7] Halcox, J.P., Tubach, F., Sazova, O., Sweet, S., Medina, J., E.s. committee, Reclassification of European patients' cardiovascular risk using the updated Systematic Coronary Risk Evaluation algorithm. Eur. J. Prev. Cardiol. 22 (2015), 200–202.
8. [8] Hippisley-Cox, J., Coupland, C., Brindle, P., Derivation and validation of QStroke score for predicting risk of ischaemic stroke in primary care and comparison with other risk scores: a prospective open cohort study. BMJ, 346, 2013, f2573.
9. [9] Verges, B., Adiels, M., Boren, J., Barrett, P.H., Watts, G.F., Chan, D., Duvillard, L., Soderlund, S., Matikainen, N., Kahri, J., Robin, I., Taskinen, M.R., Interrelationships between the kinetics of VLDL subspecies and HDL catabolism in abdominal obesity: a multicenter tracer kinetic study. J. Clin. Endocrinol. Metab. 99 (2014), 4281–4290.
10. [10] Mann, C.J., Yen, F.T., Grant, A.M., Bihain, B.E., Mechanism of plasma cholesteryl ester transfer in hypertriglyceridemia. J. Clin. Invest. 88 (1991), 2059–2066.
11. [11] Liinamaa, M.J., Hannuksela, M.L., Kesaniemi, Y.A., Savolainen, M.J., Altered transfer of cholesteryl esters and phospholipids in plasma from alcohol abusers. Arterioscler. Thromb. Vasc. Biol. 17 (1997), 2940–2947.
12. [12] Rashid, S., Genest, J., Effect of obesity on high-density lipoprotein metabolism. Obesity 15 (2007), 2875–2888.
13. [13] Tsimihodimos, V., Gazi, I., Filippatos, T., Kostapanos, M., Lagos, K., Kostara, C., Tellis, C.C., Elisaf, M., Tselepis, A.D., Plasma triglyceride levels and body mass index values are the most important determinants of prebeta-1 HDL concentrations in patients with various types of primary dyslipidemia. Atherosclerosis 208 (2010), 506–511.
14. [14] Holzer, M., Wolf, P., Curcic, S., Birner-Gruenberger, R., Weger, W., Inzinger, M., El-Gamal, D., Wadsack, C., Heinemann, A., Marsche, G., Psoriasis alters HDL composition and cholesterol efflux capacity. J. Lipid Res. 53 (2012), 1618–1624.
15. [15] Raterman, H.G., Levels, H., Voskuyl, A.E., Lems, W.F., Dijkmans, B.A., Nurmohamed, M.T., HDL protein composition alters from proatherogenic into less atherogenic and proinflammatory in rheumatoid arthritis patients responding to rituximab. Ann. Rheum. Dis. 72 (2013), 560–565.
16. [16] Gangadharan, B., Bapat, M., Rossa, J., Antrobus, R., Chittenden, D., Kampa, B., Barnes, E., Klenerman, P., Dwek, R.A., Zitzmann, N., Discovery of novel biomarker candidates for liver fibrosis in hepatitis C patients: a preliminary study. PLoS One, 7, 2012, e39603.
17. [17] Furberg, A.S., Jasienska, G., Bjurstam, N., Torjesen, P.A., Emaus, A., Lipson, S.F., Ellison, P.T., Thune, I., Metabolic and hormonal profiles: HDL cholesterol as a plausible biomarker of breast cancer risk. The Norwegian EBBA Study. Cancer Epidemiol. Biomarkers Prev. 14 (2005), 33–40.
18. [18] Melvin, J.C., Seth, D., Holmberg, L., Garmo, H., Hammar, N., Jungner, I., Walldius, G., Lambe, M., Wigertz, A., Van Hemelrijck, M., Lipid profiles and risk of breast and ovarian cancer in the Swedish AMORIS study. Cancer Epidemiol. Biomarkers Prev. 21 (2012), 1381–1384.
19. [19] Tamura, T., Inagawa, S., Hisakura, K., Enomoto, T., Ohkohchi, N., Evaluation of serum high-density lipoprotein cholesterol levels as a prognostic factor in gastric cancer patients. J. Gastroenterol. Hepatol. 27 (2012), 1635–1640.
20. [20] Chenevard, R., Hurlimann, D., Spieker, L., Bechir, M., Enseleit, F., Hermann, M., Flammer, A.J., Sudano, I., Corti, R., Luscher, T.F., Noll, G., Ruschitzka, F., Reconstituted HDL in acute coronary syndromes. Cardiovasc. Ther. 30 (2012), e51–e57.
21. [21] Krause, B.R., Remaley, A.T., Reconstituted HDL for the acute treatment of acute coronary syndrome. Curr. Opin. Lipidol. 24 (2013), 480–486.
22. [22] Calkin, A.C., Drew, B.G., Ono, A., Duffy, S.J., Gordon, M.V., Schoenwaelder, S.M., Sviridov, D., Cooper, M.E., Kingwell, B.A., Jackson, S.P., Reconstituted high-density lipoprotein attenuates platelet function in individuals with type 2 diabetes mellitus by promoting cholesterol efflux. Circulation 120 (2009), 2095–2104.
23. [23] Drew, B.G., Duffy, S.J., Formosa, M.F., Natoli, A.K., Henstridge, D.C., Penfold, S.A., Thomas, W.G., Mukhamedova, N., de Courten, B., Forbes, J.M., Yap, F.Y., Kaye, D.M., van Hall, G., Febbraio, M.A., Kemp, B.E., Sviridov, D., Steinberg, G.R., Kingwell, B.A., High-density lipoprotein modulates glucose metabolism in patients with type 2 diabetes mellitus. Circulation 119 (2009), 2103–2111.
24. [24] Foit, L., Giles, F.J., Gordon, L.I., Thaxton, C.S., Synthetic high-density lipoprotein-like nanoparticles for cancer therapy. Expert. Rev. Anticancer. Ther. 15 (2015), 27–34.
25. [25] McMahon, K.M., Foit, L., Angeloni, N.L., Giles, F.J., Gordon, L.I., Thaxton, C.S., Synthetic high-density lipoprotein-like nanoparticles as cancer therapy. Cancer Treat. Res. 166 (2015), 129–150.
26. [26] Patel, S., Drew, B.G., Nakhla, S., Duffy, S.J., Murphy, A.J., Barter, P.J., Rye, K.A., Chin-Dusting, J., Hoang, A., Sviridov, D., Celermajer, D.S., Kingwell, B.A., Reconstituted high-density lipoprotein increases plasma high-density lipoprotein anti-inflammatory properties and cholesterol efflux capacity in patients with type 2 diabetes. J. Am. Coll. Cardiol. 53 (2009), 962–971.
27. [27] Duivenvoorden, R., Tang, J., Cormode, D.P., Mieszawska, A.J., Izquierdo-Garcia, D., Ozcan, C., Otten, M.J., Zaidi, N., Lobatto, M.E., van Rijs, S.M., Priem, B., Kuan, E.L., Martel, C., Hewing, B., Sager, H., Nahrendorf, M., Randolph, G.J., Stroes, E.S., Fuster, V., Fisher, E.A., Fayad, Z.A., Mulder, W.J., A statin-loaded reconstituted high-density lipoprotein nanoparticle inhibits atherosclerotic plaque inflammation. Nat. Commun., 5, 2014, 3065.
28. [28] Tardy, C., Goffinet, M., Boubekeur, N., Ackermann, R., Sy, G., Bluteau, A., Cholez, G., Keyserling, C., Lalwani, N., Paolini, J.F., Dasseux, J.L., Barbaras, R., Baron, R., CER-001, a HDL-mimetic, stimulates the reverse lipid transport and atherosclerosis regression in high cholesterol diet-fed LDL-receptor deficient mice. Atherosclerosis 232 (2014), 110–118.
29. [29] Lou, B., Liao, X.L., Wu, M.P., Cheng, P.F., Yin, C.Y., Fei, Z., High-density lipoprotein as a potential carrier for delivery of a lipophilic antitumoral drug into hepatoma cells. World J. Gastroenterol. 11 (2005), 954–959.
30. [30] Oda, M.N., Hargreaves, P.L., Beckstead, J.A., Redmond, K.A., van Antwerpen, R., Ryan, R.O., Reconstituted high density lipoprotein enriched with the polyene antibiotic amphotericin B. J. Lipid Res. 47 (2006), 260–267.
31. [31] Burgess, B.L., Cavigiolio, G., Fannucchi, M.V., Illek, B., Forte, T.M., Oda, M.N., A phospholipid-apolipoprotein A-I nanoparticle containing amphotericin B as a drug delivery platform with cell membrane protective properties. Int. J. Pharm. 399 (2010), 148–155.
32. [32] Damiano, M.G., Mutharasan, R.K., Tripathy, S., McMahon, K.M., Thaxton, C.S., Templated high density lipoprotein nanoparticles as potential therapies and for molecular delivery. Adv. Drug Deliv. Rev. 65 (2013), 649–662.
33. [33] Shahzad, M.M., Mangala, L.S., Han, H.D., Lu, C., Bottsford-Miller, J., Nishimura, M., Mora, E.M., Lee, J.W., Stone, R.L., Pecot, C.V., Thanapprapasr, D., Roh, J.W., Gaur, P., Nair, M.P., Park, Y.Y., Sabnis, N., Deavers, M.T., Lee, J.S., Ellis, L.M., Lopez-Berestein, G., McConathy, W.J., Prokai, L., Lacko, A.G., Sood, A.K., Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles. Neoplasia 13 (2011), 309–319.
34. [34] Jones, M.K., Gu, F., Catte, A., Li, L., Segrest, J.P., “Sticky” and “promiscuous”, the yin and yang of apolipoprotein A-I termini in discoidal high-density lipoproteins: a combined computational–experimental approach. Biochemistry 50 (2011), 2249–2263.
35. [35] Camont, L., Chapman, M.J., Kontush, A., Biological activities of HDL subpopulations and their relevance to cardiovascular disease. Trends Mol. Med. 17 (2011), 594–603.
36. [36] Davidson, W.S., Thompson, T.B., The structure of apolipoprotein A-I in high density lipoproteins. J. Biol. Chem. 282 (2007), 22249–22253.
37. [37] Ajees, A.A., Anantharamaiah, G.M., Mishra, V.K., Hussain, M.M., Murthy, H.M., Crystal structure of human apolipoprotein A-I: insights into its protective effect against cardiovascular diseases. Proc. Natl. Acad. Sci. U. S. A. 103 (2006), 2126–2131.
38. [38] Segrest, J.P., Jones, M.K., Klon, A.E., Sheldahl, C.J., Hellinger, M., De Loof, H., Harvey, S.C., A detailed molecular belt model for apolipoprotein A-I in discoidal high density lipoprotein. J. Biol. Chem. 274 (1999), 31755–31758.
39. [39] Silva, R.A., Hilliard, G.M., Li, L., Segrest, J.P., Davidson, W.S., A mass spectrometric determination of the conformation of dimeric apolipoprotein A-I in discoidal high density lipoproteins. Biochemistry 44 (2005), 8600–8607.
40. [40] Borhani, D.W., Rogers, D.P., Engler, J.A., Brouillette, C.G., Crystal structure of truncated human apolipoprotein A-I suggests a lipid-bound conformation. Proc. Natl. Acad. Sci. U. S. A. 94 (1997), 12291–12296.
41. [41] Koppaka, V., Silvestro, L., Engler, J.A., Brouillette, C.G., Axelsen, P.H., The structure of human lipoprotein A-I. Evidence for the “belt” model. J. Biol. Chem. 274 (1999), 14541–14544.
42. [42] Ibanez, B., Giannarelli, C., Cimmino, G., Santos-Gallego, C.G., Alique, M., Pinero, A., Vilahur, G., Fuster, V., Badimon, L., Badimon, J.J., Recombinant HDL(Milano) exerts greater anti-inflammatory and plaque stabilizing properties than HDL(wild-type). Atherosclerosis 220 (2012), 72–77.
43. [43] Rocco, A.G., Sensi, C., Gianazza, E., Calabresi, L., Franceschini, G., Sirtori, C.R., Eberini, I., Structural and dynamic features of apolipoprotein A-I cysteine mutants, Milano and Paris, in synthetic HDL. J. Mol. Graph. Model. 29 (2010), 406–414.
44. [44] Gursky, O., Jones, M.K., Mei, X., Segrest, J.P., Atkinson, D., Structural basis for distinct functions of the naturally occurring Cys mutants of human apolipoprotein A-I. J. Lipid Res. 54 (2013), 3244–3257.
45. [45] Petrlova, J., Duong, T., Cochran, M.C., Axelsson, A., Morgelin, M., Roberts, L.M., Lagerstedt, J.O., The fibrillogenic L178H variant of apolipoprotein A-I forms helical fibrils. J. Lipid Res. 53 (2012), 390–398.
46. [46] Lagerstedt, J.O., Cavigiolio, G., Roberts, L.M., Hong, H.S., Jin, L.W., Fitzgerald, P.G., Oda, M.N., Voss, J.C., Mapping the structural transition in an amyloidogenic apolipoprotein A-I. Biochemistry 46 (2007), 9693–9699.
47. [47] Anantharamaiah, G.M., Jones, J.L., Brouillette, C.G., Schmidt, C.F., Chung, B.H., Hughes, T.A., Bhown, A.S., Segrest, J.P., Studies of synthetic peptide analogs of the amphipathic helix. Structure of complexes with dimyristoyl phosphatidylcholine. J. Biol. Chem. 260 (1985), 10248–10255.
48. [48] Datta, G., Chaddha, M., Hama, S., Navab, M., Fogelman, A.M., Garber, D.W., Mishra, V.K., Epand, R.M., Epand, R.F., Lund-Katz, S., Phillips, M.C., Segrest, J.P., Anantharamaiah, G.M., Effects of increasing hydrophobicity on the physical–chemical and biological properties of a class A amphipathic helical peptide. J. Lipid Res. 42 (2001), 1096–1104.
49. [49] Navab, M., Hough, G., Buga, G.M., Su, F., Wagner, A.C., Meriwether, D., Chattopadhyay, A., Gao, F., Grijalva, V., Danciger, J.S., Van Lenten, B.J., Org, E., Lusis, A.J., Pan, C., Anantharamaiah, G.M., Farias-Eisner, R., Smyth, S.S., Reddy, S.T., Fogelman, A.M., Transgenic 6F tomatoes act on the small intestine to prevent systemic inflammation and dyslipidemia caused by Western diet and intestinally derived lysophosphatidic acid. J. Lipid Res. 54 (2013), 3403–3418.
50. [50] Navab, M., Anantharamaiah, G.M., Hama, S., Garber, D.W., Chaddha, M., Hough, G., Lallone, R., Fogelman, A.M., Oral administration of an Apo A-I mimetic peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation 105 (2002), 290–292.
51. [51] Van Lenten, B.J., Wagner, A.C., Navab, M., Anantharamaiah, G.M., Hui, E.K., Nayak, D.P., Fogelman, A.M., D-4F, an apolipoprotein A-I mimetic peptide, inhibits the inflammatory response induced by influenza A infection of human type II pneumocytes. Circulation 110 (2004), 3252–3258.
52. [52] Van Lenten, B.J., Wagner, A.C., Anantharamaiah, G.M., Garber, D.W., Fishbein, M.C., Adhikary, L., Nayak, D.P., Hama, S., Navab, M., Fogelman, A.M., Influenza infection promotes macrophage traffic into arteries of mice that is prevented by D-4F, an apolipoprotein A-I mimetic peptide. Circulation 106 (2002), 1127–1132.
53. [53] D'Souza, W., Stonik, J.A., Murphy, A., Demosky, S.J., Sethi, A.A., Moore, X.L., Chin-Dusting, J., Remaley, A.T., Sviridov, D., Structure/function relationships of apolipoprotein a-I mimetic peptides: implications for antiatherogenic activities of high-density lipoprotein. Circ. Res. 107 (2010), 217–227.
54. [54] Rudman, D., Garcia, L.A., Abell, L.L., Akgun, S., Observations on the protein components of human plasma high- and low-density lipoproteins. Biochemistry 7 (1968), 3136–3148.
55. [55] Shore, B., Shore, V., Heterogeneity in protein subunits of human serum high-density lipoproteins. Biochemistry 7 (1968), 2773–2777.
56. [56] Davidsson, P., Hulthe, J., Fagerberg, B., Camejo, G., Proteomics of apolipoproteins and associated proteins from plasma high-density lipoproteins. Arterioscler. Thromb. Vasc. Biol. 30 (2010), 156–163.
57. [57] Zannis, V.I., Chroni, A., Kypreos, K.E., Kan, H.Y., Cesar, T.B., Zanni, E.E., Kardassis, D., Probing the pathways of chylomicron and HDL metabolism using adenovirus-mediated gene transfer. Curr. Opin. Lipidol. 15 (2004), 151–166.
58. [58] Zannis, V.I., Cole, F.S., Jackson, C.L., Kurnit, D.M., Karathanasis, S.K., Distribution of apolipoprotein A-I, C-II, C-III, and E mRNA in fetal human tissues. Time-dependent induction of apolipoprotein E mRNA by cultures of human monocyte-macrophages. Biochemistry 24 (1985), 4450–4455.
59. [59] Zannis, V.I., Chroni, A., Krieger, M., Role of apoA-I, ABCA1, LCAT, and SR-BI in the biogenesis of HDL. J. Mol. Med. 84 (2006), 276–294.
60. [60] Thacker, S.G., Rousset, X., Esmail, S., Zarzour, A., Jin, X., Collins, H.L., Sampson, M., Stonik, J., Demosky, S., Malide, D.A., Freeman, L., Vaisman, B.L., Kruth, H.S., Adelman, S.J., Remaley, A.T., Increased plasma cholesterol esterification by LCAT reduces diet-induced atherosclerosis in SR-BI knockout mice. J. Lipid Res. 56 (2015), 1282–1295.
61. [61] Jonas, A., Lecithin cholesterol acyltransferase. Biochim. Biophys. Acta 1529 (2000), 245–256.
62. [62] van Tol, A., Phospholipid transfer protein. Curr. Opin. Lipidol. 13 (2002), 135–139.
63. [63] Barter, P.J., Brewer, H.B. Jr., Chapman, M.J., Hennekens, C.H., Rader, D.J., Tall, A.R., Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 23 (2003), 160–167.
64. [64] Santamarina-Fojo, S., Gonzalez-Navarro, H., Freeman, L., Wagner, E., Nong, Z., Hepatic lipase, lipoprotein metabolism, and atherogenesis. Arterioscler. Thromb. Vasc. Biol. 24 (2004), 1750–1754.
65. [65] Massey, J.B., Pownall, H.J., Cholesterol is a determinant of the structures of discoidal high density lipoproteins formed by the solubilization of phospholipid membranes by apolipoprotein A-I. Biochim. Biophys. Acta 1781 (2008), 245–253.
66. [66] Nguyen, S.D., Oorni, K., Lee-Rueckert, M., Pihlajamaa, T., Metso, J., Jauhiainen, M., Kovanen, P.T., Spontaneous remodeling of HDL particles at acidic pH enhances their capacity to induce cholesterol efflux from human macrophage foam cells. J. Lipid Res. 53 (2012), 2115–2125.
67. [67] Rye, K.A., Barter, P.J., The influence of apolipoproteins on the structure and function of spheroidal, reconstituted high density lipoproteins. J. Biol. Chem. 269 (1994), 10298–10303.
68. [68] Maugeais, C., Tietge, U.J., Broedl, U.C., Marchadier, D., Cain, W., McCoy, M.G., Lund-Katz, S., Glick, J.M., Rader, D.J., Dose-dependent acceleration of high-density lipoprotein catabolism by endothelial lipase. Circulation 108 (2003), 2121–2126.
69. [69] Wolfrum, C., Poy, M.N., Stoffel, M., Apolipoprotein M is required for prebeta-HDL formation and cholesterol efflux to HDL and protects against atherosclerosis. Nat. Med. 11 (2005), 418–422.
70. [70] Lusa, S., Jauhiainen, M., Metso, J., Somerharju, P., Ehnholm, C., The mechanism of human plasma phospholipid transfer protein-induced enlargement of high-density lipoprotein particles: evidence for particle fusion. Biochem. J. 313:Pt 1 (1996), 275–282.
71. [71] Pagler, T.A., Rhode, S., Neuhofer, A., Laggner, H., Strobl, W., Hinterndorfer, C., Volf, I., Pavelka, M., Eckhardt, E.R., van der Westhuyzen, D.R., Schutz, G.J., Stangl, H., SR-BI-mediated high density lipoprotein (HDL) endocytosis leads to HDL resecretion facilitating cholesterol efflux. J. Biol. Chem. 281 (2006), 11193–11204.
72. [72] Rohrl, C., Stangl, H., HDL endocytosis and resecretion. Biochim. Biophys. Acta 1831 (2013), 1626–1633.
73. [73] Nakamura, K., Kennedy, M.A., Baldan, A., Bojanic, D.D., Lyons, K., Edwards, P.A., Expression and regulation of multiple murine ATP-binding cassette transporter G1 mRNAs/isoforms that stimulate cellular cholesterol efflux to high density lipoprotein. J. Biol. Chem. 279 (2004), 45980–45989.
74. [74] Martinez, L.O., Jacquet, S., Esteve, J.P., Rolland, C., Cabezon, E., Champagne, E., Pineau, T., Georgeaud, V., Walker, J.E., Terce, F., Collet, X., Perret, B., Barbaras, R., Ectopic beta-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis. Nature 421 (2003), 75–79.
75. [75] Jackson, R.L., Gotto, A.M., Stein, O., Stein, Y., A comparative study on the removal of cellular lipids from Landschutz ascites cells by human plasma apolipoproteins. J. Biol. Chem. 250 (1975), 7204–7209.
76. [76] Annema, W., Tietge, U.J., Regulation of reverse cholesterol transport—a comprehensive appraisal of available animal studies. Nutr. Metab., 9, 2012, 25.
77. [77] Rosenson, R.S., Brewer, H.B. Jr., Davidson, W.S., Fayad, Z.A., Fuster, V., Goldstein, J., Hellerstein, M., Jiang, X.C., Phillips, M.C., Rader, D.J., Remaley, A.T., Rothblat, G.H., Tall, A.R., Yvan-Charvet, L., Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation 125 (2012), 1905–1919.
78. [78] Hardy, J., Selkoe, D.J., The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297 (2002), 353–356.
79. [79] Lewis, T.L., Cao, D., Lu, H., Mans, R.A., Su, Y.R., Jungbauer, L., Linton, M.F., Fazio, S., LaDu, M.J., Li, L., Overexpression of human apolipoprotein A-I preserves cognitive function and attenuates neuroinflammation and cerebral amyloid angiopathy in a mouse model of Alzheimer disease. J. Biol. Chem. 285 (2010), 36958–36968.
80. [80] Robert, J., Stukas, S., Button, E., Cheng, W.H., Lee, M., Fan, J., Wilkinson, A., Kulic, I., Wright, S.D., Wellington, C.L., Reconstituted high-density lipoproteins acutely reduce soluble brain Abeta levels in symptomatic APP/PS1 mice. Biochim. Biophys. Acta 1862 (2016), 1027–1036.
81. [81] Shaw, J.A., Bobik, A., Murphy, A., Kanellakis, P., Blombery, P., Mukhamedova, N., Woollard, K., Lyon, S., Sviridov, D., Dart, A.M., Infusion of reconstituted high-density lipoprotein leads to acute changes in human atherosclerotic plaque. Circ. Res. 103 (2008), 1084–1091.
82. [82] Liu, X., Suo, R., Xiong, S.L., Zhang, Q.H., Yi, G.H., HDL drug carriers for targeted therapy. Clin. Chim. Acta 415 (2013), 94–100.
83. [83] Wolfrum, C., Shi, S., Jayaprakash, K.N., Jayaraman, M., Wang, G., Pandey, R.K., Rajeev, K.G., Nakayama, T., Charrise, K., Ndungo, E.M., Zimmermann, T., Koteliansky, V., Manoharan, M., Stoffel, M., Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat. Biotechnol. 25 (2007), 1149–1157.
84. [84] Zhang, Z., Cao, W., Jin, H., Lovell, J.F., Yang, M., Ding, L., Chen, J., Corbin, I., Luo, Q., Zheng, G., Biomimetic nanocarrier for direct cytosolic drug delivery. Angew. Chem. 48 (2009), 9171–9175.
85. [85] Sherman, C.B., Peterson, S.J., Frishman, W.H., Apolipoprotein A-I mimetic peptides: a potential new therapy for the prevention of atherosclerosis. Cardiol. Rev. 18 (2010), 141–147.
86. [86] Murakami, T., Wijagkanalan, W., Hashida, M., Tsuchida, K., Intracellular drug delivery by genetically engineered high-density lipoprotein nanoparticles. Nanomedicine 5 (2010), 867–879.
87. [87] Iovannisci, D.M., Beckstead, J.A., Ryan, R.O., Targeting nanodisks via a single chain variable antibody–apolipoprotein chimera. Biochem. Biophys. Res. Commun. 379 (2009), 466–469.
88. [88] Uno, Y., Piao, W., Miyata, K., Nishina, K., Mizusawa, H., Yokota, T., High-density lipoprotein facilitates in vivo delivery of alpha-tocopherol-conjugated short-interfering RNA to the brain. Hum. Gene Ther. 22 (2011), 711–719.
89. [89] Ryan, R.O., Nanobiotechnology applications of reconstituted high density lipoprotein. J. Nanobiotechnol., 8, 2010, 28.
90. [90] Redmond, K.A., Nguyen, T.S., Ryan, R.O., All-trans-retinoic acid nanodisks. Int. J. Pharm. 339 (2007), 246–250.
91. [91] Park, J.H., Tallman, M.S., Treatment of acute promyelocytic leukemia without cytotoxic chemotherapy. Oncology 25 (2011), 733–741.
92. [92] Ghosh, M., Singh, A.T., Xu, W., Sulchek, T., Gordon, L.I., Ryan, R.O., Curcumin nanodisks: formulation and characterization. Nanomedicine 7 (2011), 162–167.
93. [93] Wang, J., Jia, J., Liu, J., He, H., Zhang, W., Li, Z., Tumor targeting effects of a novel modified paclitaxel-loaded discoidal mimic high density lipoproteins. Drug Deliv. 20 (2013), 356–363.
94. [94] Zhang, M., Jia, J., Liu, J., He, H.L., Liu, L.H., A novel modified paclitaxel-loaded discoidal recombinant high-density lipoproteins: preparation, characterizations and in vivo evaluation. Asian J. Pharm. Sci. 8 (2013), 11–18.
95. [95] Segrest, J.P., Jones, M.K., Catte, A., MD simulations suggest important surface differences between reconstituted and circulating spherical HDL. J. Lipid Res. 54 (2013), 2718–2732.
96. [96] Zhang, W., Li, J., Liu, J., Wu, Z., Xu, Y., Wang, J., Tanshinone IIA-loaded reconstituted high density lipoproteins: atherosclerotic plaque targeting mechanism in a foam cell model and pharmacokinetics in rabbits. Pharmazie 67 (2012), 324–330.
97. [97] Sabnis, N., Nair, M., Israel, M., McConathy, W.J., Lacko, A.G., Enhanced solubility and functionality of valrubicin (AD-32) against cancer cells upon encapsulation into biocompatible nanoparticles. Int. J. Nanomedicine 7 (2012), 975–983.
98. [98] Sabnis, N., Pratap, S., Akopova, I., Bowman, P.W., Lacko, A.G., Pre-clinical evaluation of rHDL encapsulated retinoids for the treatment of neuroblastoma. Front. Pediatr., 1, 2013, 6.
99. [99] McConathy, W.J., Nair, M.P., Paranjape, S., Mooberry, L., Lacko, A.G., Evaluation of synthetic/reconstituted high-density lipoproteins as delivery vehicles for paclitaxel. Anti-Cancer Drugs 19 (2008), 183–188.
100. [100] Yin, H., Kanasty, R.L., Eltoukhy, A.A., Vegas, A.J., Dorkin, J.R., Anderson, D.G., Non-viral vectors for gene-based therapy. Nat. Rev. Genet. 15 (2014), 541–555.
101. [101] Dobrovolskaia, M.A., McNeil, S.E., Strategy for selecting nanotechnology carriers to overcome immunological and hematological toxicities challenging clinical translation of nucleic acid-based therapeutics. Expert Opin. Drug Deliv. 12 (2015), 1163–1175.
102. [102] Bali, K.K., Kuner, R., Noncoding RNAs: key molecules in understanding and treating pain. Trends Mol. Med. 20 (2014), 437–448.
103. [103] Vickers, K.C., Palmisano, B.T., Shoucri, B.M., Shamburek, R.D., Remaley, A.T., MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat. Cell Biol. 13 (2011), 423–433.
104. [104] Soutschek, J., Akinc, A., Bramlage, B., Charisse, K., Constien, R., Donoghue, M., Elbashir, S., Geick, A., Hadwiger, P., Harborth, J., John, M., Kesavan, V., Lavine, G., Pandey, R.K., Racie, T., Rajeev, K.G., Rohl, I., Toudjarska, I., Wang, G., Wuschko, S., Bumcrot, D., Koteliansky, V., Limmer, S., Manoharan, M., Vornlocher, H.P., Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432 (2004), 173–178.
105. [105] Tripathy, S., Vinokour, E., McMahon, K.M., Volpert, O.V., Thaxton, C.S., High density lipoprotein nanoparticles deliver RNAi to endothelial cells to inhibit angiogenesis. Part. Part. Syst. Charact. 31 (2014), 1141–1150.
106. [106] Ding, Y., Wang, W., Feng, M., Wang, Y., Zhou, J., Ding, X., Zhou, X., Liu, C., Wang, R., Zhang, Q., A biomimetic nanovector-mediated targeted cholesterol-conjugated siRNA delivery for tumor gene therapy. Biomaterials 33 (2012), 8893–8905.
107. [107] Nakayama, T., Butler, J.S., Sehgal, A., Severgnini, M., Racie, T., Sharman, J., Ding, F., Morskaya, S.S., Brodsky, J., Tchangov, L., Kosovrasti, V., Meys, M., Nechev, L., Wang, G., Peng, C.G., Fang, Y., Maier, M., Rajeev, K.G., Li, R., Hettinger, J., Barros, S., Clausen, V., Zhang, X., Wang, Q., Hutabarat, R., Dokholyan, N.V., Wolfrum, C., Manoharan, M., Kotelianski, V., Stoffel, M., Sah, D.W., Harnessing a physiologic mechanism for siRNA delivery with mimetic lipoprotein particles. Mol. Ther. 20 (2012), 1582–1589.
108. [108] Lee, H., Kim, S.I., Shin, D., Yoon, Y., Choi, T.H., Cheon, G.J., Kim, M., Hepatic siRNA delivery using recombinant human apolipoprotein A-I in mice. Biochem. Biophys. Res. Commun. 378 (2009), 192–196.
109. [109] Janas, T., Janas, T., Yarus, M., Specific RNA binding to ordered phospholipid bilayers. Nucleic Acids Res. 34 (2006), 2128–2136.
110. [110] Mitchell, P.S., Parkin, R.K., Kroh, E.M., Fritz, B.R., Wyman, S.K., Pogosova-Agadjanyan, E.L., Peterson, A., Noteboom, J., O'Briant, K.C., Allen, A., Lin, D.W., Urban, N., Drescher, C.W., Knudsen, B.S., Stirewalt, D.L., Gentleman, R., Vessella, R.L., Nelson, P.S., Martin, D.B., Tewari, M., Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 10513–10518.
111. [111] Qiu, X., Mistry, A., Ammirati, M.J., Chrunyk, B.A., Clark, R.W., Cong, Y., Culp, J.S., Danley, D.E., Freeman, T.B., Geoghegan, K.F., Griffor, M.C., Hawrylik, S.J., Hayward, C.M., Hensley, P., Hoth, L.R., Karam, G.A., Lira, M.E., Lloyd, D.B., McGrath, K.M., Stutzman-Engwall, K.J., Subashi, A.K., Subashi, T.A., Thompson, J.F., Wang, I.K., Zhao, H., Seddon, A.P., Crystal structure of cholesteryl ester transfer protein reveals a long tunnel and four bound lipid molecules. Nat. Struct. Mol. Biol. 14 (2007), 106–113.
112. [112] McMahon, K.M., Mutharasan, R.K., Tripathy, S., Veliceasa, D., Bobeica, M., Shumaker, D.K., Luthi, A.J., Helfand, B.T., Ardehali, H., Mirkin, C.A., Volpert, O., Thaxton, C.S., Biomimetic high density lipoprotein nanoparticles for nucleic acid delivery. Nano Lett. 11 (2011), 1208–1214.
113. [113] Perez-Medina, C., Tang, J., Abdel-Atti, D., Hogstad, B., Merad, M., Fisher, E.A., Fayad, Z.A., Lewis, J.S., Mulder, W.J., Reiner, T., PET imaging of tumor-associated macrophages with 89Zr-labeled high-density lipoprotein nanoparticles. J. Nucl. Med. 56 (2015), 1272–1277.
114. [114] Shen, Z.T., Zheng, S., Gounis, M.J., Sigalov, A.B., Diagnostic magnetic resonance imaging of atherosclerosis in apolipoprotein E knockout mouse model using macrophage-targeted gadolinium-containing synthetic lipopeptide nanoparticles. PLoS One, 10, 2015, e0143453.
115. [115] Zhang, Z., Chen, J., Ding, L., Jin, H., Lovell, J.F., Corbin, I.R., Cao, W., Lo, P.C., Yang, M., Tsao, M.S., Luo, Q., Zheng, G., HDL-mimicking peptide-lipid nanoparticles with improved tumor targeting. Small 6 (2010), 430–437.
116. [116] Sanchez-Gaytan, B.L., Fay, F., Lobatto, M.E., Tang, J., Ouimet, M., Kim, Y., van der Staay, S.E., van Rijs, S.M., Priem, B., Zhang, L., Fisher, E.A., Moore, K.J., Langer, R., Fayad, Z.A., Mulder, W.J., HDL-mimetic PLGA nanoparticle to target atherosclerosis plaque macrophages. Bioconjug. Chem. 26 (2015), 443–451.
117. 2 nanoparticles on monocytes and macrophages in serum. Nanomedicine 9 (2014), 2481–2497.
118. [118] Gu, X., Zhang, W., Liu, J., Shaw, J.P., Shen, Y., Xu, Y., Lu, H., Wu, Z., Preparation and characterization of a lovastatin-loaded protein-free nanostructured lipid carrier resembling high-density lipoprotein and evaluation of its targeting to foam cells. AAPS PharmSciTech 12 (2011), 1200–1208.
119. [119] Huang, M., Hu, M., Song, Q., Song, H., Huang, J., Gu, X., Wang, X., Chen, J., Kang, T., Feng, X., Jiang, D., Zheng, G., Chen, H., Gao, X., GM1-modified lipoprotein-like nanoparticle: multifunctional nanoplatform for the combination therapy of Alzheimer's disease. ACS Nano 9 (2015), 10801–10816.
120. [120] Murakami, T., Okamoto, H., Kim, H., Structural and functional changes in high-density lipoprotein induced by chemical modification. Biomater. Sci. 3 (2015), 712–715.
121. [121] Fischer, N.O., Weilhammer, D.R., Dunkle, A., Thomas, C., Hwang, M., Corzett, M., Lychak, C., Mayer, W., Urbin, S., Collette, N., Chiun Chang, J., Loots, G.G., Rasley, A., Blanchette, C.D., Evaluation of nanolipoprotein particles (NLPs) as an in vivo delivery platform. PLoS One, 9, 2014, e93342.
122. [122] Acton, S., Rigotti, A., Landschulz, K.T., Xu, S., Hobbs, H.H., Krieger, M., Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science 271 (1996), 518–520.
123. [123] Azhar, S., Nomoto, A., Leers-Sucheta, S., Reaven, E., Simultaneous induction of an HDL receptor protein (SR-BI) and the selective uptake of HDL-cholesteryl esters in a physiologically relevant steroidogenic cell model. J. Lipid Res. 39 (1998), 1616–1628.
124. [124] During, A., Dawson, H.D., Harrison, E.H., Carotenoid transport is decreased and expression of the lipid transporters SR-BI, NPC1L1, and ABCA1 is downregulated in Caco-2 cells treated with ezetimibe. J. Nutr. 135 (2005), 2305–2312.
125. [125] Rigotti, A., Acton, S.L., Krieger, M., The class B scavenger receptors SR-BI and CD36 are receptors for anionic phospholipids. J. Biol. Chem. 270 (1995), 16221–16224.
126. [126] Pei, Y., Chen, X., Aboutouk, D., Fuller, M.T., Dadoo, O., Yu, P., White, E.J., Igdoura, S.A., Trigatti, B.L., SR-BI in bone marrow derived cells protects mice from diet induced coronary artery atherosclerosis and myocardial infarction. PLoS One, 8, 2013, e72492.
127. [127] Mineo, C., Shaul, P.W., HDL stimulation of endothelial nitric oxide synthase: a novel mechanism of HDL action. Trends Cardiovasc. Med. 13 (2003), 226–231.
128. [128] Grewal, T., de Diego, I., Kirchhoff, M.F., Tebar, F., Heeren, J., Rinninger, F., Enrich, C., High density lipoprotein-induced signaling of the MAPK pathway involves scavenger receptor type BI-mediated activation of Ras. J. Biol. Chem. 278 (2003), 16478–16481.
129. [129] Tolle, M., Pawlak, A., Schuchardt, M., Kawamura, A., Tietge, U.J., Lorkowski, S., Keul, P., Assmann, G., Chun, J., Levkau, B., van der Giet, M., Nofer, J.R., HDL-associated lysosphingolipids inhibit NAD(P)H oxidase-dependent monocyte chemoattractant protein-1 production. Arterioscler. Thromb. Vasc. Biol. 28 (2008), 1542–1548.
130. [130] Graf, G.A., Connell, P.M., van der Westhuyzen, D.R., Smart, E.J., The class B, type I scavenger receptor promotes the selective uptake of high density lipoprotein cholesterol ethers into caveolae. J. Biol. Chem. 274 (1999), 12043–12048.
131. [131] Zheng, Y., Liu, Y., Jin, H., Pan, S., Qian, Y., Huang, C., Zeng, Y., Luo, Q., Zeng, M., Zhang, Z., Scavenger receptor B1 is a potential biomarker of human nasopharyngeal carcinoma and its growth is inhibited by HDL-mimetic nanoparticles. Theranostics 3 (2013), 477–486.
132. [132] Yang, S., Damiano, M.G., Zhang, H., Tripathy, S., Luthi, A.J., Rink, J.S., Ugolkov, A.V., Singh, A.T., Dave, S.S., Gordon, L.I., Thaxton, C.S., Biomimetic, synthetic HDL nanostructures for lymphoma. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 2511–2516.
133. [133] Lin, Q., Chen, J., Jin, H., Ng, K.K., Yang, M., Cao, W., Ding, L., Zhang, Z., Zheng, G., Efficient systemic delivery of siRNA by using high-density lipoprotein-mimicking peptide lipid nanoparticles. Nanomedicine 7 (2012), 1813–1825.
134. [134] Lacko, A.G., Nair, M., Paranjape, S., Johnso, S., McConathy, W.J., High density lipoprotein complexes as delivery vehicles for anticancer drugs. Anticancer Res. 22 (2002), 2045–2049.
135. [135] Oram, J.F., The cholesterol mobilizing transporter ABCA1 as a new therapeutic target for cardiovascular disease. Trends Cardiovasc. Med. 12 (2002), 170–175.
136. [136] Boadu, E., Francis, G.A., The role of vesicular transport in ABCA1-dependent lipid efflux and its connection with NPC pathways. J. Mol. Med. 84 (2006), 266–275.
137. [137] Hassan, H.H., Denis, M., Lee, D.Y., Iatan, I., Nyholt, D., Ruel, I., Krimbou, L., Genest, J., Identification of an ABCA1-dependent phospholipid-rich plasma membrane apolipoprotein A-I binding site for nascent HDL formation: implications for current models of HDL biogenesis. J. Lipid Res. 48 (2007), 2428–2442.
138. [138] Vedhachalam, C., Ghering, A.B., Davidson, W.S., Lund-Katz, S., Rothblat, G.H., Phillips, M.C., ABCA1-induced cell surface binding sites for ApoA-I. Arterioscler. Thromb. Vasc. Biol. 27 (2007), 1603–1609.
139. [139] Du, X.M., Kim, M.J., Hou, L., Le Goff, W., Chapman, M.J., Van Eck, M., Curtiss, L.K., Burnett, J.R., Cartland, S.P., Quinn, C.M., Kockx, M., Kontush, A., Rye, K.A., Kritharides, L., Jessup, W., HDL particle size is a critical determinant of ABCA1-mediated macrophage cellular cholesterol export. Circ. Res. 116 (2015), 1133–1142.
140. [140] Landry, Y.D., Denis, M., Nandi, S., Bell, S., Vaughan, A.M., Zha, X., ATP-binding cassette transporter A1 expression disrupts raft membrane microdomains through its ATPase-related functions. J. Biol. Chem. 281 (2006), 36091–36101.
141. [141] Nandi, S., Ma, L., Denis, M., Karwatsky, J., Li, Z., Jiang, X.C., Zha, X., ABCA1-mediated cholesterol efflux generates microparticles in addition to HDL through processes governed by membrane rigidity. J. Lipid Res. 50 (2009), 456–466.
142. [142] Mulya, A., Lee, J.Y., Gebre, A.K., Thomas, M.J., Colvin, P.L., Parks, J.S., Minimal lipidation of pre-beta HDL by ABCA1 results in reduced ability to interact with ABCA1. Arterioscler. Thromb. Vasc. Biol. 27 (2007), 1828–1836.
143. [143] Negi, S.I., Brautbar, A., Virani, S.S., Anand, A., Polisecki, E., Asztalos, B.F., Ballantyne, C.M., Schaefer, E.J., Jones, P.H., A novel mutation in the ABCA1 gene causing an atypical phenotype of Tangier disease. J. Clin. Lipidol. 7 (2013), 82–87.
144. [144] Brunham, L.R., Kang, M.H., Van Karnebeek, C., Sadananda, S.N., Collins, J.A., Zhang, L.H., Sayson, B., Miao, F., Stockler, S., Frohlich, J., Cassiman, D., Rabkin, S.W., Hayden, M.R., Clinical, biochemical, and molecular characterization of novel mutations in ABCA1 in families with Tangier disease. JIMD Rep. 18 (2015), 51–62.
145. [145] Oram, J.F., ABCA1 as a new therapeutic target for treating cardiovascular disease. Drug News Perspect. 15 (2002), 24–28.
146. [146] Huang, C.X., Zhang, Y.L., The target of regulating the ATP-binding cassette A1 protein (ABCA1): promoting ABCA1-mediated cholesterol efflux in different cells. Curr. Pharm. Biotechnol. 14 (2013), 623–631.
147. [147] Lindegaard, M.L., Wassif, C.A., Vaisman, B., Amar, M., Wasmuth, E.V., Shamburek, R., Nielsen, L.B., Remaley, A.T., Porter, F.D., Characterization of placental cholesterol transport: ABCA1 is a potential target for in utero therapy of Smith–Lemli–Opitz syndrome. Hum. Mol. Genet. 17 (2008), 3806–3813.
148. [148] Chou, J.L., Huang, R.L., Shay, J., Chen, L.Y., Lin, S.J., Yan, P.S., Chao, W.T., Lai, Y.H., Lai, Y.L., Chao, T.K., Lee, C.I., Tai, C.K., Wu, S.F., Nephew, K.P., Huang, T.H., Lai, H.C., Chan, M.W., Hypermethylation of the TGF-beta target, ABCA1 is associated with poor prognosis in ovarian cancer patients. Clin. Epigenetics, 7, 2015, 1.
149. [149] Christoffersen, C., Nielsen, L.B., Axler, O., Andersson, A., Johnsen, A.H., Dahlback, B., Isolation and characterization of human apolipoprotein M-containing lipoproteins. J. Lipid Res. 47 (2006), 1833–1843.
150. [150] Mulya, A., Seo, J., Brown, A.L., Gebre, A.K., Boudyguina, E., Shelness, G.S., Parks, J.S., Apolipoprotein M expression increases the size of nascent pre beta HDL formed by ATP binding cassette transporter A1. J. Lipid Res. 51 (2010), 514–524.
151. [151] Liu, M., Seo, J., Allegood, J., Bi, X., Zhu, X., Boudyguina, E., Gebre, A.K., Avni, D., Shah, D., Sorci-Thomas, M.G., Thomas, M.J., Shelness, G.S., Spiegel, S., Parks, J.S., Hepatic apolipoprotein M (apoM) overexpression stimulates formation of larger apoM/sphingosine 1-phosphate-enriched plasma high density lipoprotein. J. Biol. Chem. 289 (2014), 2801–2814.
152. [152] Christoffersen, C., Jauhiainen, M., Moser, M., Porse, B., Ehnholm, C., Boesl, M., Dahlback, B., Nielsen, L.B., Effect of apolipoprotein M on high density lipoprotein metabolism and atherosclerosis in low density lipoprotein receptor knock-out mice. J. Biol. Chem. 283 (2008), 1839–1847.
153. [153] Elsoe, S., Christoffersen, C., Luchoomun, J., Turner, S., Nielsen, L.B., Apolipoprotein M promotes mobilization of cellular cholesterol in vivo. Biochim. Biophys. Acta 1831 (2013), 1287–1292.
154. [154] Wilkerson, B.A., Grass, G.D., Wing, S.B., Argraves, W.S., Argraves, K.M., Sphingosine 1-phosphate (S1P) carrier-dependent regulation of endothelial barrier: high density lipoprotein (HDL)-S1P prolongs endothelial barrier enhancement as compared with albumin-S1P via effects on levels, trafficking, and signaling of S1P1. J. Biol. Chem. 287 (2012), 44645–44653.
155. [155] Christoffersen, C., Obinata, H., Kumaraswamy, S.B., Galvani, S., Ahnstrom, J., Sevvana, M., Egerer-Sieber, C., Muller, Y.A., Hla, T., Nielsen, L.B., Dahlback, B., Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M. Proc. Natl. Acad. Sci. U. S. A. 108 (2011), 9613–9618.
156. [156] Karuna, R., Park, R., Othman, A., Holleboom, A.G., Motazacker, M.M., Sutter, I., Kuivenhoven, J.A., Rohrer, L., Matile, H., Hornemann, T., Stoffel, M., Rentsch, K.M., von Eckardstein, A., Plasma levels of sphingosine-1-phosphate and apolipoprotein M in patients with monogenic disorders of HDL metabolism. Atherosclerosis 219 (2011), 855–863.
157. [157] Blaho, V.A., Galvani, S., Engelbrecht, E., Liu, C., Swendeman, S.L., Kono, M., Proia, R.L., Steinman, L., Han, M.H., Hla, T., HDL-bound sphingosine-1-phosphate restrains lymphopoiesis and neuroinflammation. Nature 523 (2015), 342–346.
158. [158] Siow, D.L., Anderson, C.D., Berdyshev, E.V., Skobeleva, A., Pitson, S.M., Wattenberg, B.W., Intracellular localization of sphingosine kinase 1 alters access to substrate pools but does not affect the degradative fate of sphingosine-1-phosphate. J. Lipid Res. 51 (2010), 2546–2559.
159. [159] Maceyka, M., Sankala, H., Hait, N.C., Le Stunff, H., Liu, H., Toman, R., Collier, C., Zhang, M., Satin, L.S., Merrill, A.H. Jr., Milstien, S., Spiegel, S., SphK1 and SphK2, sphingosine kinase isoenzymes with opposing functions in sphingolipid metabolism. J. Biol. Chem. 280 (2005), 37118–37129.
160. [160] Spiegel, S., Milstien, S., Sphingosine 1-phosphate, a key cell signaling molecule. J. Biol. Chem. 277 (2002), 25851–25854.
161. [161] Mandala, S.M., Sphingosine-1-phosphate phosphatases. Prostaglandins 64 (2001), 143–156.
162. [162] Bourquin, F., Riezman, H., Capitani, G., Grutter, M.G., Structure and function of sphingosine-1-phosphate lyase, a key enzyme of sphingolipid metabolism. Structure 18 (2010), 1054–1065.
163. [163] Hisano, Y., Kobayashi, N., Kawahara, A., Yamaguchi, A., Nishi, T., The sphingosine 1-phosphate transporter, SPNS2, functions as a transporter of the phosphorylated form of the immunomodulating agent FTY720. J. Biol. Chem. 286 (2011), 1758–1766.
164. [164] Lee, Y.M., Venkataraman, K., Hwang, S.I., Han, D.K., Hla, T., A novel method to quantify sphingosine 1-phosphate by immobilized metal affinity chromatography (IMAC). Prostaglandins Other Lipid Mediat. 84 (2007), 154–162.
165. [165] Wang, D., Zhao, Z., Caperell-Grant, A., Yang, G., Mok, S.C., Liu, J., Bigsby, R.M., Xu, Y., S1P differentially regulates migration of human ovarian cancer and human ovarian surface epithelial cells. Mol. Cancer Ther. 7 (2008), 1993–2002.
166. [166] Maceyka, M., Harikumar, K.B., Milstien, S., Spiegel, S., Sphingosine-1-phosphate signaling and its role in disease. Trends Cell Biol. 22 (2012), 50–60.
167. [167] Pyne, N.J., Tonelli, F., Lim, K.G., Long, J.S., Edwards, J., Pyne, S., Sphingosine 1-phosphate signalling in cancer. Biochem. Soc. Trans. 40 (2012), 94–100.
168. [168] Maceyka, M., Spiegel, S., Sphingolipid metabolites in inflammatory disease. Nature 510 (2014), 58–67.
169. [169] Wang, L., Sammani, S., Moreno-Vinasco, L., Letsiou, E., Wang, T., Camp, S.M., Bittman, R., Garcia, J.G., Dudek, S.M., FTY720 (s)-phosphonate preserves sphingosine 1-phosphate receptor 1 expression and exhibits superior barrier protection to FTY720 in acute lung injury. Crit. Care Med. 42 (2014), e189–e199.
170. [170] Oo, M.L., Thangada, S., Wu, M.T., Liu, C.H., Macdonald, T.L., Lynch, K.R., Lin, C.Y., Hla, T., Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor. J. Biol. Chem. 282 (2007), 9082–9089.
171. [171] Pinschewer, D.D., Ochsenbein, A.F., Odermatt, B., Brinkmann, V., Hengartner, H., Zinkernagel, R.M., FTY720 immunosuppression impairs effector T cell peripheral homing without affecting induction, expansion, and memory. J. Immunol. 164 (2000), 5761–5770.
172. [172] Nofer, J.R., Bot, M., Brodde, M., Taylor, P.J., Salm, P., Brinkmann, V., van Berkel, T., Assmann, G., Biessen, E.A., FTY720, a synthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 115 (2007), 501–508.
173. [173] Klingenberg, R., Nofer, J.R., Rudling, M., Bea, F., Blessing, E., Preusch, M., Grone, H.J., Katus, H.A., Hansson, G.K., Dengler, T.J., Sphingosine-1-phosphate analogue FTY720 causes lymphocyte redistribution and hypercholesterolemia in ApoE-deficient mice. Arterioscler. Thromb. Vasc. Biol. 27 (2007), 2392–2399.
174. [174] Das, A., Tanner, S., Barker, D.A., Green, D., Botchwey, E.A., Delivery of S1P receptor-targeted drugs via biodegradable polymer scaffolds enhances bone regeneration in a critical size cranial defect. J. Biomed. Mater. Res. A 102 (2014), 1210–1218.
175. [175] Cannon, R.E., Peart, J.C., Hawkins, B.T., Campos, C.R., Miller, D.S., Targeting blood–brain barrier sphingolipid signaling reduces basal P-glycoprotein activity and improves drug delivery to the brain. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), 15930–15935.
176. [176] Cheng, Q., Ma, S., Lin, D., Mei, Y., Gong, H., Lei, L., Chen, Y., Zhao, Y., Hu, B., Wu, Y., Yu, X., Zhao, L., Liu, H., The S1P1 receptor-selective agonist CYM-5442 reduces the severity of acute GVHD by inhibiting macrophage recruitment. Cell. Mol. Immunol. 12 (2015), 681–691.
177. [177] McDonald, R.A., Pyne, S., Pyne, N.J., Grant, A., Wainwright, C.L., Wadsworth, R.M., The sphingosine kinase inhibitor N,N-dimethylsphingosine inhibits neointimal hyperplasia. Br. J. Pharmacol. 159 (2010), 543–553.
178. [178] Seo, Y.J., Pritzl, C.J., Vijayan, M., Blake, C.R., McClain, M.E., Hahm, B., Sphingosine analogue AAL-R increases TLR7-mediated dendritic cell responses via p38 and type I IFN signaling pathways. J. Immunol. 188 (2012), 4759–4768.
179. [179] Yang, L., Weng, W., Sun, Z.X., Fu, X.J., Ma, J., Zhuang, W.F., SphK1 inhibitor II (SKI-II) inhibits acute myelogenous leukemia cell growth in vitro and in vivo. Biochem. Biophys. Res. Commun. 460 (2015), 903–908.
180. [180] John, A.L.S., Ang, W.X., Huang, M.N., Kunder, C.A., Chan, E.W., Gunn, M.D., Abraham, S.N., S1P-dependent trafficking of intracellular yersinia pestis through lymph nodes establishes Buboes and systemic infection. Immunity 41 (2014), 440–450.
181. [181] Sabbadini, R.A., Sphingosine-1-phosphate antibodies as potential agents in the treatment of cancer and age-related macular degeneration. Br. J. Pharmacol. 162 (2011), 1225–1238.
182. [182] Parton, R.G., Simons, K., The multiple faces of caveolae. Nat. Rev. Mol. Cell Biol. 8 (2007), 185–194.
183. [183] Couet, J., Belanger, M.M., Roussel, E., Drolet, M.C., Cell biology of caveolae and caveolin. Adv. Drug Deliv. Rev. 49 (2001), 223–235.
184. [184] Cohen, A.W., Hnasko, R., Schubert, W., Lisanti, M.P., Role of caveolae and caveolins in health and disease. Physiol. Rev. 84 (2004), 1341–1379.
185. [185] Fielding, C.J., Fielding, P.E., Cholesterol and caveolae: structural and functional relationships. Biochim. Biophys. Acta 1529 (2000), 210–222.
186. [186] Frank, P.G., Pedraza, A., Cohen, D.E., Lisanti, M.P., Adenovirus-mediated expression of caveolin-1 in mouse liver increases plasma high-density lipoprotein levels. Biochemistry 40 (2001), 10892–10900.
187. [187] Razani, B., Combs, T.P., Wang, X.B., Frank, P.G., Park, D.S., Russell, R.G., Li, M., Tang, B., Jelicks, L.A., Scherer, P.E., Lisanti, M.P., Caveolin-1-deficient mice are lean, resistant to diet-induced obesity, and show hypertriglyceridemia with adipocyte abnormalities. J. Biol. Chem. 277 (2002), 8635–8647.
188. [188] Fraser, R., Dobbs, B.R., Rogers, G.W., Lipoproteins and the liver sieve: the role of the fenestrated sinusoidal endothelium in lipoprotein metabolism, atherosclerosis, and cirrhosis. Hepatology 21 (1995), 863–874.
189. [189] Storey, S.M., Gallegos, A.M., Atshaves, B.P., McIntosh, A.L., Martin, G.G., Parr, R.D., Landrock, K.K., Kier, A.B., Ball, J.M., Schroeder, F., Selective cholesterol dynamics between lipoproteins and caveolae/lipid rafts. Biochemistry 46 (2007), 13891–13906.
190. [190] Heimerl, S., Liebisch, G., Le Lay, S., Bottcher, A., Wiesner, P., Lindtner, S., Kurzchalia, T.V., Simons, K., Schmitz, G., Caveolin-1 deficiency alters plasma lipid and lipoprotein profiles in mice. Biochem. Biophys. Res. Commun. 367 (2008), 826–833.
191. [191] Lin, Y.C., Ma, C., Hsu, W.C., Lo, H.F., Yang, V.C., Molecular interaction between caveolin-1 and ABCA1 on high-density lipoprotein-mediated cholesterol efflux in aortic endothelial cells. Cardiovasc. Res. 75 (2007), 575–583.
192. [192] Chao, W.T., Tsai, S.H., Lin, Y.C., Lin, W.W., Yang, V.C., Cellular localization and interaction of ABCA1 and caveolin-1 in aortic endothelial cells after HDL incubation. Biochem. Biophys. Res. Commun. 332 (2005), 743–749.
193. [193] Lin, Q., Chen, J., Ng, K.K., Cao, W., Zhang, Z., Zheng, G., Imaging the cytosolic drug delivery mechanism of HDL-like nanoparticles. Pharm. Res. 31 (2014), 1438–1449.
194. [194] Lopes-de-Araujo, J., Neves, A.R., Gouveia, V.M., Moura, C.C., Nunes, C., Reis, S., Oxaprozin-loaded lipid nanoparticles towards overcoming NSAIDs side-effects. Pharm. Res. 33 (2016), 301–314.
195. [195] Zhu, Y., Wu, Y., Zhang, H., Wang, Z., Wang, S., Qian, Y., Zhu, R., Enhanced anti-metastatic activity of etoposide using layered double hydroxide nano particles. J. Biomed. Nanotechnol. 11 (2015), 2158–2168.
196. [196] Tariq, M., Alam, M.A., Singh, A.T., Panda, A.K., Talegaonkar, S., Surface decorated nanoparticles as surrogate carriers for improved transport and absorption of epirubicin across the gastrointestinal tract: pharmacokinetic and pharmacodynamic investigations. Int. J. Pharm. 501 (2016), 18–31.
197. [197] Garnett, D.J., Caveolae as a target to quench autoinduction of the metastatic phenotype in lung cancer. J. Cancer Res. Clin. Oncol., 2015.
198. [198] Yin, S., Huai, J., Chen, X., Yang, Y., Zhang, X., Gan, Y., Wang, G., Gu, X., Li, J., Intracellular delivery and antitumor effects of a redox-responsive polymeric paclitaxel conjugate based on hyaluronic acid. Acta Biomater. 26 (2015), 274–285.
199. [199] Neves, A.R., Queiroz, J.F., Costa Lima, S.A., Figueiredo, F., Fernandes, R., Reis, S., Cellular uptake and transcytosis of lipid-based nanoparticles across the intestinal barrier: relevance for oral drug delivery. J. Colloid Interface Sci. 463 (2016), 258–265.
200. [200] Murakami, T., Phospholipid nanodisc engineering for drug delivery systems. Biotechnol. J. 7 (2012), 762–767.